id	sid	tid	token	lemma	pos
cord-263267-oj7rmy8m	1	1	key	key	NN
cord-263267-oj7rmy8m	1	2	:	:	:
cord-263267-oj7rmy8m	2	1	cord-263267-oj7rmy8	cord-263267-oj7rmy8	NNP
cord-263267-oj7rmy8m	2	2	m	m	NNP
cord-263267-oj7rmy8m	2	3	authors	author	NNS
cord-263267-oj7rmy8m	2	4	:	:	:
cord-263267-oj7rmy8m	2	5	Taccone	Taccone	NNP
cord-263267-oj7rmy8m	2	6	,	,	,
cord-263267-oj7rmy8m	2	7	Fabio	Fabio	NNP
cord-263267-oj7rmy8m	2	8	S	S	NNP
cord-263267-oj7rmy8m	2	9	;	;	:
cord-263267-oj7rmy8m	2	10	Gorham	Gorham	NNP
cord-263267-oj7rmy8m	2	11	,	,	,
cord-263267-oj7rmy8m	2	12	Julie	Julie	NNP
cord-263267-oj7rmy8m	2	13	;	;	:
cord-263267-oj7rmy8m	2	14	Vincent	Vincent	NNP
cord-263267-oj7rmy8m	2	15	,	,	,
cord-263267-oj7rmy8m	2	16	Jean	Jean	NNP
cord-263267-oj7rmy8m	2	17	-	-	HYPH
cord-263267-oj7rmy8m	2	18	Louis	Louis	NNP
cord-263267-oj7rmy8m	2	19	title	title	NN
cord-263267-oj7rmy8m	2	20	:	:	:
cord-263267-oj7rmy8m	2	21	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-263267-oj7rmy8m	2	22	in	in	IN
cord-263267-oj7rmy8m	2	23	the	the	DT
cord-263267-oj7rmy8m	2	24	management	management	NN
cord-263267-oj7rmy8m	2	25	of	of	IN
cord-263267-oj7rmy8m	2	26	critically	critically	RB
cord-263267-oj7rmy8m	2	27	ill	ill	JJ
cord-263267-oj7rmy8m	2	28	patients	patient	NNS
cord-263267-oj7rmy8m	2	29	with	with	IN
cord-263267-oj7rmy8m	2	30	COVID-19	covid-19	VB
cord-263267-oj7rmy8m	2	31	:	:	:
cord-263267-oj7rmy8m	2	32	the	the	DT
cord-263267-oj7rmy8m	2	33	need	need	NN
cord-263267-oj7rmy8m	2	34	for	for	IN
cord-263267-oj7rmy8m	2	35	an	an	DT
cord-263267-oj7rmy8m	2	36	evidence	evidence	NN
cord-263267-oj7rmy8m	2	37	base	base	NN
cord-263267-oj7rmy8m	2	38	date	date	NN
cord-263267-oj7rmy8m	2	39	:	:	:
cord-263267-oj7rmy8m	2	40	2020	2020	CD
cord-263267-oj7rmy8m	2	41	-	-	HYPH
cord-263267-oj7rmy8m	2	42	04	04	CD
cord-263267-oj7rmy8m	2	43	-	-	SYM
cord-263267-oj7rmy8m	2	44	15	15	CD
cord-263267-oj7rmy8m	2	45	journal	journal	NN
cord-263267-oj7rmy8m	2	46	:	:	:
cord-263267-oj7rmy8m	2	47	Lancet	Lancet	NNP
cord-263267-oj7rmy8m	2	48	Respir	Respir	NNP
cord-263267-oj7rmy8m	2	49	Med	Med	NNP
cord-263267-oj7rmy8m	2	50	DOI	doi	NN
cord-263267-oj7rmy8m	2	51	:	:	:
cord-263267-oj7rmy8m	2	52	10.1016	10.1016	CD
cord-263267-oj7rmy8m	2	53	/	/	SYM
cord-263267-oj7rmy8m	2	54	s2213	s2213	NN
cord-263267-oj7rmy8m	2	55	-	-	HYPH
cord-263267-oj7rmy8m	2	56	2600(20)30172	2600(20)30172	CD
cord-263267-oj7rmy8m	2	57	-	-	HYPH
cord-263267-oj7rmy8m	2	58	7	7	CD
cord-263267-oj7rmy8m	2	59	sha	sha	NN
cord-263267-oj7rmy8m	2	60	:	:	:
cord-263267-oj7rmy8m	3	1	cfef8928ebc57961e1a604a099878dc839434688	cfef8928ebc57961e1a604a099878dc839434688	NNP
cord-263267-oj7rmy8m	3	2	doc_id	doc_id	CD
cord-263267-oj7rmy8m	3	3	:	:	:
cord-263267-oj7rmy8m	3	4	263267	263267	CD
cord-263267-oj7rmy8m	3	5	cord_uid	cord_uid	NNS
cord-263267-oj7rmy8m	3	6	:	:	:
cord-263267-oj7rmy8m	4	1	oj7rmy8	oj7rmy8	NNP
cord-263267-oj7rmy8m	5	1	m	m	NNP
cord-263267-oj7rmy8m	5	2	nan	nan	NNP
cord-263267-oj7rmy8m	6	1	With	with	IN
cord-263267-oj7rmy8m	6	2	the	the	DT
cord-263267-oj7rmy8m	6	3	rapid	rapid	JJ
cord-263267-oj7rmy8m	6	4	spread	spread	NN
cord-263267-oj7rmy8m	6	5	of	of	IN
cord-263267-oj7rmy8m	6	6	the	the	DT
cord-263267-oj7rmy8m	6	7	novel	novel	JJ
cord-263267-oj7rmy8m	6	8	severe	severe	JJ
cord-263267-oj7rmy8m	6	9	acute	acute	JJ
cord-263267-oj7rmy8m	6	10	respiratory	respiratory	JJ
cord-263267-oj7rmy8m	6	11	syndrome	syndrome	NN
cord-263267-oj7rmy8m	6	12	coronavirus	coronavirus	NN
cord-263267-oj7rmy8m	6	13	2	2	CD
cord-263267-oj7rmy8m	6	14	(	(	-LRB-
cord-263267-oj7rmy8m	6	15	SARS	SARS	NNP
cord-263267-oj7rmy8m	6	16	-	-	HYPH
cord-263267-oj7rmy8m	6	17	CoV-2	CoV-2	NNP
cord-263267-oj7rmy8m	6	18	)	)	-RRB-
cord-263267-oj7rmy8m	6	19	,	,	,
cord-263267-oj7rmy8m	6	20	critical	critical	JJ
cord-263267-oj7rmy8m	6	21	care	care	NN
cord-263267-oj7rmy8m	6	22	physicians	physician	NNS
cord-263267-oj7rmy8m	6	23	are	be	VBP
cord-263267-oj7rmy8m	6	24	seeing	see	VBG
cord-263267-oj7rmy8m	6	25	increasing	increase	VBG
cord-263267-oj7rmy8m	6	26	numbers	number	NNS
cord-263267-oj7rmy8m	6	27	of	of	IN
cord-263267-oj7rmy8m	6	28	patients	patient	NNS
cord-263267-oj7rmy8m	6	29	with	with	IN
cord-263267-oj7rmy8m	6	30	acute	acute	JJ
cord-263267-oj7rmy8m	6	31	respiratory	respiratory	JJ
cord-263267-oj7rmy8m	6	32	failure	failure	NN
cord-263267-oj7rmy8m	6	33	secondary	secondary	JJ
cord-263267-oj7rmy8m	6	34	to	to	IN
cord-263267-oj7rmy8m	6	35	coronavirus	coronavirus	NN
cord-263267-oj7rmy8m	6	36	disease	disease	NN
cord-263267-oj7rmy8m	6	37	2019	2019	CD
cord-263267-oj7rmy8m	6	38	(	(	-LRB-
cord-263267-oj7rmy8m	6	39	COVID-19	COVID-19	NNP
cord-263267-oj7rmy8m	6	40	)	)	-RRB-
cord-263267-oj7rmy8m	6	41	and	and	CC
cord-263267-oj7rmy8m	6	42	reporting	report	VBG
cord-263267-oj7rmy8m	6	43	mortality	mortality	NN
cord-263267-oj7rmy8m	6	44	rates	rate	NNS
cord-263267-oj7rmy8m	6	45	of	of	IN
cord-263267-oj7rmy8m	6	46	40	40	CD
cord-263267-oj7rmy8m	6	47	-	-	SYM
cord-263267-oj7rmy8m	6	48	65	65	CD
cord-263267-oj7rmy8m	6	49	%	%	NN
cord-263267-oj7rmy8m	6	50	for	for	IN
cord-263267-oj7rmy8m	6	51	those	those	DT
cord-263267-oj7rmy8m	6	52	requiring	require	VBG
cord-263267-oj7rmy8m	6	53	mechanical	mechanical	JJ
cord-263267-oj7rmy8m	6	54	ventilation	ventilation	NN
cord-263267-oj7rmy8m	6	55	1	1	CD
cord-263267-oj7rmy8m	6	56	-strikingly	-strikingly	RB
cord-263267-oj7rmy8m	6	57	higher	high	JJR
cord-263267-oj7rmy8m	6	58	than	than	IN
cord-263267-oj7rmy8m	6	59	the	the	DT
cord-263267-oj7rmy8m	6	60	mortality	mortality	NN
cord-263267-oj7rmy8m	6	61	rates	rate	NNS
cord-263267-oj7rmy8m	6	62	reported	report	VBN
cord-263267-oj7rmy8m	6	63	for	for	IN
cord-263267-oj7rmy8m	6	64	the	the	DT
cord-263267-oj7rmy8m	6	65	more	more	RBR
cord-263267-oj7rmy8m	6	66	typical	typical	JJ
cord-263267-oj7rmy8m	6	67	acute	acute	JJ
cord-263267-oj7rmy8m	6	68	respiratory	respiratory	JJ
cord-263267-oj7rmy8m	6	69	distress	distress	NN
cord-263267-oj7rmy8m	6	70	syndrome	syndrome	NN
cord-263267-oj7rmy8m	6	71	associated	associate	VBN
cord-263267-oj7rmy8m	6	72	with	with	IN
cord-263267-oj7rmy8m	6	73	other	other	JJ
cord-263267-oj7rmy8m	6	74	diseases	disease	NNS
cord-263267-oj7rmy8m	6	75	.	.	.
cord-263267-oj7rmy8m	7	1	2	2	LS
cord-263267-oj7rmy8m	8	1	The	the	DT
cord-263267-oj7rmy8m	8	2	focus	focus	NN
cord-263267-oj7rmy8m	8	3	of	of	IN
cord-263267-oj7rmy8m	8	4	therapeutic	therapeutic	JJ
cord-263267-oj7rmy8m	8	5	intervention	intervention	NN
cord-263267-oj7rmy8m	8	6	has	have	VBZ
cord-263267-oj7rmy8m	8	7	therefore	therefore	RB
cord-263267-oj7rmy8m	8	8	been	be	VBN
cord-263267-oj7rmy8m	8	9	not	not	RB
cord-263267-oj7rmy8m	8	10	only	only	RB
cord-263267-oj7rmy8m	8	11	to	to	TO
cord-263267-oj7rmy8m	8	12	reverse	reverse	VB
cord-263267-oj7rmy8m	8	13	hypoxaemia	hypoxaemia	NN
cord-263267-oj7rmy8m	8	14	and	and	CC
cord-263267-oj7rmy8m	8	15	provide	provide	VB
cord-263267-oj7rmy8m	8	16	adequate	adequate	JJ
cord-263267-oj7rmy8m	8	17	organ	organ	NN
cord-263267-oj7rmy8m	8	18	support	support	NN
cord-263267-oj7rmy8m	8	19	,	,	,
cord-263267-oj7rmy8m	8	20	but	but	CC
cord-263267-oj7rmy8m	8	21	also	also	RB
cord-263267-oj7rmy8m	8	22	to	to	TO
cord-263267-oj7rmy8m	8	23	decrease	decrease	VB
cord-263267-oj7rmy8m	8	24	viral	viral	JJ
cord-263267-oj7rmy8m	8	25	load	load	NN
cord-263267-oj7rmy8m	8	26	and	and	CC
cord-263267-oj7rmy8m	8	27	thus	thus	RB
cord-263267-oj7rmy8m	8	28	limit	limit	VB
cord-263267-oj7rmy8m	8	29	disease	disease	NN
cord-263267-oj7rmy8m	8	30	severity	severity	NN
cord-263267-oj7rmy8m	8	31	.	.	.
cord-263267-oj7rmy8m	9	1	In	in	IN
cord-263267-oj7rmy8m	9	2	addition	addition	NN
cord-263267-oj7rmy8m	9	3	to	to	IN
cord-263267-oj7rmy8m	9	4	several	several	JJ
cord-263267-oj7rmy8m	9	5	antiviral	antiviral	JJ
cord-263267-oj7rmy8m	9	6	agents	agent	NNS
cord-263267-oj7rmy8m	9	7	,	,	,
cord-263267-oj7rmy8m	9	8	antimalarial	antimalarial	JJ
cord-263267-oj7rmy8m	9	9	drugs	drug	NNS
cord-263267-oj7rmy8m	9	10	have	have	VBP
cord-263267-oj7rmy8m	9	11	been	be	VBN
cord-263267-oj7rmy8m	9	12	proposed	propose	VBN
cord-263267-oj7rmy8m	9	13	as	as	IN
cord-263267-oj7rmy8m	9	14	treatments	treatment	NNS
cord-263267-oj7rmy8m	9	15	that	that	WDT
cord-263267-oj7rmy8m	9	16	could	could	MD
cord-263267-oj7rmy8m	9	17	reduce	reduce	VB
cord-263267-oj7rmy8m	9	18	transmission	transmission	NN
cord-263267-oj7rmy8m	9	19	of	of	IN
cord-263267-oj7rmy8m	9	20	the	the	DT
cord-263267-oj7rmy8m	9	21	virus	virus	NN
cord-263267-oj7rmy8m	9	22	.	.	.
cord-263267-oj7rmy8m	10	1	In	in	IN
cord-263267-oj7rmy8m	10	2	-	-	HYPH
cord-263267-oj7rmy8m	10	3	vitro	vitro	FW
cord-263267-oj7rmy8m	10	4	studies	study	NNS
cord-263267-oj7rmy8m	10	5	have	have	VBP
cord-263267-oj7rmy8m	10	6	shown	show	VBN
cord-263267-oj7rmy8m	10	7	that	that	IN
cord-263267-oj7rmy8m	10	8	chloroquine	chloroquine	NN
cord-263267-oj7rmy8m	10	9	and	and	CC
cord-263267-oj7rmy8m	10	10	hydroxychloroquine	hydroxychloroquine	NN
cord-263267-oj7rmy8m	10	11	can	can	MD
cord-263267-oj7rmy8m	10	12	both	both	CC
cord-263267-oj7rmy8m	10	13	inhibit	inhibit	VB
cord-263267-oj7rmy8m	10	14	SARS	SARS	NNP
cord-263267-oj7rmy8m	10	15	-	-	HYPH
cord-263267-oj7rmy8m	10	16	CoV-2	CoV-2	NNP
cord-263267-oj7rmy8m	10	17	transmission	transmission	NN
cord-263267-oj7rmy8m	10	18	,	,	,
cord-263267-oj7rmy8m	10	19	3	3	CD
cord-263267-oj7rmy8m	10	20	-	-	SYM
cord-263267-oj7rmy8m	10	21	5	5	CD
cord-263267-oj7rmy8m	10	22	through	through	IN
cord-263267-oj7rmy8m	10	23	alkalinisation	alkalinisation	NN
cord-263267-oj7rmy8m	10	24	of	of	IN
cord-263267-oj7rmy8m	10	25	the	the	DT
cord-263267-oj7rmy8m	10	26	intracellular	intracellular	JJ
cord-263267-oj7rmy8m	10	27	phagolysosome	phagolysosome	NN
cord-263267-oj7rmy8m	10	28	,	,	,
cord-263267-oj7rmy8m	10	29	which	which	WDT
cord-263267-oj7rmy8m	10	30	prevents	prevent	VBZ
cord-263267-oj7rmy8m	10	31	virion	virion	NN
cord-263267-oj7rmy8m	10	32	fusion	fusion	NN
cord-263267-oj7rmy8m	10	33	and	and	CC
cord-263267-oj7rmy8m	10	34	uncoating	uncoating	NN
cord-263267-oj7rmy8m	10	35	and	and	CC
cord-263267-oj7rmy8m	10	36	,	,	,
cord-263267-oj7rmy8m	10	37	therefore	therefore	RB
cord-263267-oj7rmy8m	10	38	,	,	,
cord-263267-oj7rmy8m	10	39	viral	viral	JJ
cord-263267-oj7rmy8m	10	40	spread	spread	NN
cord-263267-oj7rmy8m	10	41	.	.	.
cord-263267-oj7rmy8m	11	1	Early	early	JJ
cord-263267-oj7rmy8m	11	2	results	result	NNS
cord-263267-oj7rmy8m	11	3	from	from	IN
cord-263267-oj7rmy8m	11	4	clinical	clinical	JJ
cord-263267-oj7rmy8m	11	5	studies	study	NNS
cord-263267-oj7rmy8m	11	6	conducted	conduct	VBN
cord-263267-oj7rmy8m	11	7	in	in	IN
cord-263267-oj7rmy8m	11	8	China	China	NNP
cord-263267-oj7rmy8m	11	9	suggest	suggest	VBP
cord-263267-oj7rmy8m	11	10	that	that	IN
cord-263267-oj7rmy8m	11	11	chloroquine	chloroquine	NN
cord-263267-oj7rmy8m	11	12	use	use	NN
cord-263267-oj7rmy8m	11	13	might	may	MD
cord-263267-oj7rmy8m	11	14	have	have	VB
cord-263267-oj7rmy8m	11	15	been	be	VBN
cord-263267-oj7rmy8m	11	16	associated	associate	VBN
cord-263267-oj7rmy8m	11	17	with	with	IN
cord-263267-oj7rmy8m	11	18	reduced	reduce	VBN
cord-263267-oj7rmy8m	11	19	fever	fever	NN
cord-263267-oj7rmy8m	11	20	,	,	,
cord-263267-oj7rmy8m	11	21	increased	increase	VBN
cord-263267-oj7rmy8m	11	22	resolution	resolution	NN
cord-263267-oj7rmy8m	11	23	of	of	IN
cord-263267-oj7rmy8m	11	24	lung	lung	NN
cord-263267-oj7rmy8m	11	25	lesions	lesion	NNS
cord-263267-oj7rmy8m	11	26	on	on	IN
cord-263267-oj7rmy8m	11	27	CT	CT	NNP
cord-263267-oj7rmy8m	11	28	,	,	,
cord-263267-oj7rmy8m	11	29	and	and	CC
cord-263267-oj7rmy8m	11	30	delayed	delay	VBN
cord-263267-oj7rmy8m	11	31	disease	disease	NN
cord-263267-oj7rmy8m	11	32	progression	progression	NN
cord-263267-oj7rmy8m	11	33	.	.	.
cord-263267-oj7rmy8m	12	1	6,7	6,7	CD
cord-263267-oj7rmy8m	12	2	Results	result	NNS
cord-263267-oj7rmy8m	12	3	of	of	IN
cord-263267-oj7rmy8m	12	4	two	two	CD
cord-263267-oj7rmy8m	12	5	French	french	JJ
cord-263267-oj7rmy8m	12	6	studies	study	NNS
cord-263267-oj7rmy8m	12	7	suggested	suggest	VBD
cord-263267-oj7rmy8m	12	8	that	that	IN
cord-263267-oj7rmy8m	12	9	hydroxychloroquine	hydroxychloroquine	NNP
cord-263267-oj7rmy8m	12	10	could	could	MD
cord-263267-oj7rmy8m	12	11	reduce	reduce	VB
cord-263267-oj7rmy8m	12	12	the	the	DT
cord-263267-oj7rmy8m	12	13	viral	viral	JJ
cord-263267-oj7rmy8m	12	14	load	load	NN
cord-263267-oj7rmy8m	12	15	in	in	IN
cord-263267-oj7rmy8m	12	16	patients	patient	NNS
cord-263267-oj7rmy8m	12	17	with	with	IN
cord-263267-oj7rmy8m	12	18	COVID-19	COVID-19	NNP
cord-263267-oj7rmy8m	12	19	in	in	IN
cord-263267-oj7rmy8m	12	20	particular	particular	JJ
cord-263267-oj7rmy8m	12	21	,	,	,
cord-263267-oj7rmy8m	12	22	if	if	IN
cord-263267-oj7rmy8m	12	23	combined	combine	VBN
cord-263267-oj7rmy8m	12	24	with	with	IN
cord-263267-oj7rmy8m	12	25	azithromycin	azithromycin	NNP
cord-263267-oj7rmy8m	12	26	8,9	8,9	CD
cord-263267-oj7rmy8m	12	27	(	(	-LRB-
cord-263267-oj7rmy8m	12	28	table	table	NN
cord-263267-oj7rmy8m	12	29	)	)	-RRB-
cord-263267-oj7rmy8m	12	30	.	.	.
cord-263267-oj7rmy8m	13	1	On	on	IN
cord-263267-oj7rmy8m	13	2	the	the	DT
cord-263267-oj7rmy8m	13	3	basis	basis	NN
cord-263267-oj7rmy8m	13	4	of	of	IN
cord-263267-oj7rmy8m	13	5	these	these	DT
cord-263267-oj7rmy8m	13	6	preliminary	preliminary	JJ
cord-263267-oj7rmy8m	13	7	findings	finding	NNS
cord-263267-oj7rmy8m	13	8	,	,	,
cord-263267-oj7rmy8m	13	9	chloroquine	chloroquine	NN
cord-263267-oj7rmy8m	13	10	and	and	CC
cord-263267-oj7rmy8m	13	11	hydroxychloroquine	hydroxychloroquine	NN
cord-263267-oj7rmy8m	13	12	have	have	VBP
cord-263267-oj7rmy8m	13	13	been	be	VBN
cord-263267-oj7rmy8m	13	14	prescribed	prescribe	VBN
cord-263267-oj7rmy8m	13	15	to	to	IN
cord-263267-oj7rmy8m	13	16	patients	patient	NNS
cord-263267-oj7rmy8m	13	17	to	to	TO
cord-263267-oj7rmy8m	13	18	reduce	reduce	VB
cord-263267-oj7rmy8m	13	19	the	the	DT
cord-263267-oj7rmy8m	13	20	length	length	NN
cord-263267-oj7rmy8m	13	21	of	of	IN
cord-263267-oj7rmy8m	13	22	hospital	hospital	NN
cord-263267-oj7rmy8m	13	23	stay	stay	NN
cord-263267-oj7rmy8m	13	24	and	and	CC
cord-263267-oj7rmy8m	13	25	improve	improve	VB
cord-263267-oj7rmy8m	13	26	the	the	DT
cord-263267-oj7rmy8m	13	27	evolution	evolution	NN
cord-263267-oj7rmy8m	13	28	of	of	IN
cord-263267-oj7rmy8m	13	29	COVID-19-related	covid-19-related	JJ
cord-263267-oj7rmy8m	13	30	pneumonia	pneumonia	NN
cord-263267-oj7rmy8m	13	31	.	.	.
cord-263267-oj7rmy8m	14	1	Nevertheless	nevertheless	RB
cord-263267-oj7rmy8m	14	2	,	,	,
cord-263267-oj7rmy8m	14	3	the	the	DT
cord-263267-oj7rmy8m	14	4	recently	recently	RB
cord-263267-oj7rmy8m	14	5	published	publish	VBN
cord-263267-oj7rmy8m	14	6	Surviving	Surviving	NNP
cord-263267-oj7rmy8m	14	7	Sepsis	Sepsis	NNP
cord-263267-oj7rmy8m	14	8	Campaign	Campaign	NNP
cord-263267-oj7rmy8m	14	9	guidelines	guideline	NNS
cord-263267-oj7rmy8m	14	10	on	on	IN
cord-263267-oj7rmy8m	14	11	the	the	DT
cord-263267-oj7rmy8m	14	12	management	management	NN
cord-263267-oj7rmy8m	14	13	of	of	IN
cord-263267-oj7rmy8m	14	14	critically	critically	RB
cord-263267-oj7rmy8m	14	15	ill	ill	JJ
cord-263267-oj7rmy8m	14	16	patients	patient	NNS
cord-263267-oj7rmy8m	14	17	with	with	IN
cord-263267-oj7rmy8m	14	18	COVID-19	COVID-19	NNP
cord-263267-oj7rmy8m	14	19	concluded	conclude	VBD
cord-263267-oj7rmy8m	14	20	that	that	IN
cord-263267-oj7rmy8m	14	21	there	there	EX
cord-263267-oj7rmy8m	14	22	was	be	VBD
cord-263267-oj7rmy8m	14	23	insufficient	insufficient	JJ
cord-263267-oj7rmy8m	14	24	evidence	evidence	NN
cord-263267-oj7rmy8m	14	25	to	to	TO
cord-263267-oj7rmy8m	14	26	offer	offer	VB
cord-263267-oj7rmy8m	14	27	any	any	DT
cord-263267-oj7rmy8m	14	28	recommendation	recommendation	NN
cord-263267-oj7rmy8m	14	29	on	on	IN
cord-263267-oj7rmy8m	14	30	the	the	DT
cord-263267-oj7rmy8m	14	31	routine	routine	JJ
cord-263267-oj7rmy8m	14	32	use	use	NN
cord-263267-oj7rmy8m	14	33	of	of	IN
cord-263267-oj7rmy8m	14	34	these	these	DT
cord-263267-oj7rmy8m	14	35	drugs	drug	NNS
cord-263267-oj7rmy8m	14	36	in	in	IN
cord-263267-oj7rmy8m	14	37	patients	patient	NNS
cord-263267-oj7rmy8m	14	38	admitted	admit	VBN
cord-263267-oj7rmy8m	14	39	to	to	IN
cord-263267-oj7rmy8m	14	40	the	the	DT
cord-263267-oj7rmy8m	14	41	intensive	intensive	JJ
cord-263267-oj7rmy8m	14	42	care	care	NN
cord-263267-oj7rmy8m	14	43	unit	unit	NN
cord-263267-oj7rmy8m	14	44	(	(	-LRB-
cord-263267-oj7rmy8m	14	45	ICU	ICU	NNP
cord-263267-oj7rmy8m	14	46	)	)	-RRB-
cord-263267-oj7rmy8m	14	47	.	.	.
cord-263267-oj7rmy8m	15	1	10	10	CD
cord-263267-oj7rmy8m	15	2	How	how	WRB
cord-263267-oj7rmy8m	15	3	can	can	MD
cord-263267-oj7rmy8m	15	4	we	-PRON-	PRP
cord-263267-oj7rmy8m	15	5	explain	explain	VB
cord-263267-oj7rmy8m	15	6	these	these	DT
cord-263267-oj7rmy8m	15	7	discrepancies	discrepancy	NNS
cord-263267-oj7rmy8m	15	8	and	and	CC
cord-263267-oj7rmy8m	15	9	how	how	WRB
cord-263267-oj7rmy8m	15	10	should	should	MD
cord-263267-oj7rmy8m	15	11	antimalarial	antimalarial	JJ
cord-263267-oj7rmy8m	15	12	drugs	drug	NNS
cord-263267-oj7rmy8m	15	13	be	be	VB
cord-263267-oj7rmy8m	15	14	used	use	VBN
cord-263267-oj7rmy8m	15	15	in	in	IN
cord-263267-oj7rmy8m	15	16	the	the	DT
cord-263267-oj7rmy8m	15	17	clinical	clinical	JJ
cord-263267-oj7rmy8m	15	18	management	management	NN
cord-263267-oj7rmy8m	15	19	of	of	IN
cord-263267-oj7rmy8m	15	20	patients	patient	NNS
cord-263267-oj7rmy8m	15	21	in	in	IN
cord-263267-oj7rmy8m	15	22	the	the	DT
cord-263267-oj7rmy8m	15	23	ICU	ICU	NNP
cord-263267-oj7rmy8m	15	24	with	with	IN
cord-263267-oj7rmy8m	15	25	severe	severe	JJ
cord-263267-oj7rmy8m	15	26	COVID-19	covid-19	NN
cord-263267-oj7rmy8m	15	27	?	?	.
cord-263267-oj7rmy8m	16	1	First	first	RB
cord-263267-oj7rmy8m	16	2	,	,	,
cord-263267-oj7rmy8m	16	3	hydroxychloroquine	hydroxychloroquine	NNP
cord-263267-oj7rmy8m	16	4	is	be	VBZ
cord-263267-oj7rmy8m	16	5	not	not	RB
cord-263267-oj7rmy8m	16	6	expensive	expensive	JJ
cord-263267-oj7rmy8m	16	7	,	,	,
cord-263267-oj7rmy8m	16	8	is	be	VBZ
cord-263267-oj7rmy8m	16	9	readily	readily	RB
cord-263267-oj7rmy8m	16	10	available	available	JJ
cord-263267-oj7rmy8m	16	11	,	,	,
cord-263267-oj7rmy8m	16	12	and	and	CC
cord-263267-oj7rmy8m	16	13	seems	seem	VBZ
cord-263267-oj7rmy8m	16	14	to	to	TO
cord-263267-oj7rmy8m	16	15	be	be	VB
cord-263267-oj7rmy8m	16	16	safe	safe	JJ
cord-263267-oj7rmy8m	16	17	.	.	.
cord-263267-oj7rmy8m	17	1	However	however	RB
cord-263267-oj7rmy8m	17	2	,	,	,
cord-263267-oj7rmy8m	17	3	clinical	clinical	JJ
cord-263267-oj7rmy8m	17	4	observations	observation	NNS
cord-263267-oj7rmy8m	17	5	of	of	IN
cord-263267-oj7rmy8m	17	6	the	the	DT
cord-263267-oj7rmy8m	17	7	effects	effect	NNS
cord-263267-oj7rmy8m	17	8	of	of	IN
cord-263267-oj7rmy8m	17	9	this	this	DT
cord-263267-oj7rmy8m	17	10	drug	drug	NN
cord-263267-oj7rmy8m	17	11	in	in	IN
cord-263267-oj7rmy8m	17	12	patients	patient	NNS
cord-263267-oj7rmy8m	17	13	with	with	IN
cord-263267-oj7rmy8m	17	14	COVID-19	COVID-19	NNP
cord-263267-oj7rmy8m	17	15	have	have	VBP
cord-263267-oj7rmy8m	17	16	not	not	RB
cord-263267-oj7rmy8m	17	17	included	include	VBN
cord-263267-oj7rmy8m	17	18	critically	critically	RB
cord-263267-oj7rmy8m	17	19	ill	ill	JJ
cord-263267-oj7rmy8m	17	20	patients	patient	NNS
cord-263267-oj7rmy8m	17	21	who	who	WP
cord-263267-oj7rmy8m	17	22	are	be	VBP
cord-263267-oj7rmy8m	17	23	receiving	receive	VBG
cord-263267-oj7rmy8m	17	24	several	several	JJ
cord-263267-oj7rmy8m	17	25	other	other	JJ
cord-263267-oj7rmy8m	17	26	medications	medication	NNS
cord-263267-oj7rmy8m	17	27	and	and	CC
cord-263267-oj7rmy8m	17	28	have	have	VBP
cord-263267-oj7rmy8m	17	29	organ	organ	NN
cord-263267-oj7rmy8m	17	30	failure	failure	NN
cord-263267-oj7rmy8m	17	31	,	,	,
cord-263267-oj7rmy8m	17	32	such	such	JJ
cord-263267-oj7rmy8m	17	33	as	as	IN
cord-263267-oj7rmy8m	17	34	hepatic	hepatic	JJ
cord-263267-oj7rmy8m	17	35	or	or	CC
cord-263267-oj7rmy8m	17	36	renal	renal	JJ
cord-263267-oj7rmy8m	17	37	dysfunction	dysfunction	NN
cord-263267-oj7rmy8m	17	38	,	,	,
cord-263267-oj7rmy8m	17	39	which	which	WDT
cord-263267-oj7rmy8m	17	40	might	may	MD
cord-263267-oj7rmy8m	17	41	influence	influence	VB
cord-263267-oj7rmy8m	17	42	drug	drug	NN
cord-263267-oj7rmy8m	17	43	metabolism	metabolism	NN
cord-263267-oj7rmy8m	17	44	and	and	CC
cord-263267-oj7rmy8m	17	45	potentially	potentially	RB
cord-263267-oj7rmy8m	17	46	increase	increase	VB
cord-263267-oj7rmy8m	17	47	the	the	DT
cord-263267-oj7rmy8m	17	48	risk	risk	NN
cord-263267-oj7rmy8m	17	49	of	of	IN
cord-263267-oj7rmy8m	17	50	adverse	adverse	JJ
cord-263267-oj7rmy8m	17	51	events	event	NNS
cord-263267-oj7rmy8m	17	52	.	.	.
cord-263267-oj7rmy8m	18	1	Second	second	JJ
cord-263267-oj7rmy8m	18	2	,	,	,
cord-263267-oj7rmy8m	18	3	clinical	clinical	JJ
cord-263267-oj7rmy8m	18	4	data	datum	NNS
cord-263267-oj7rmy8m	18	5	on	on	IN
cord-263267-oj7rmy8m	18	6	hydroxychloroquine	hydroxychloroquine	NNP
cord-263267-oj7rmy8m	18	7	are	be	VBP
cord-263267-oj7rmy8m	18	8	far	far	RB
cord-263267-oj7rmy8m	18	9	from	from	IN
cord-263267-oj7rmy8m	18	10	convincing	convince	VBG
cord-263267-oj7rmy8m	18	11	.	.	.
cord-263267-oj7rmy8m	19	1	The	the	DT
cord-263267-oj7rmy8m	19	2	first	first	JJ
cord-263267-oj7rmy8m	19	3	study	study	NN
cord-263267-oj7rmy8m	19	4	reported	report	VBN
cord-263267-oj7rmy8m	19	5	by	by	IN
cord-263267-oj7rmy8m	19	6	Philippe	Philippe	NNP
cord-263267-oj7rmy8m	19	7	Gautret	Gautret	NNP
cord-263267-oj7rmy8m	19	8	and	and	CC
cord-263267-oj7rmy8m	19	9	colleagues	colleague	NNS
cord-263267-oj7rmy8m	19	10	,	,	,
cord-263267-oj7rmy8m	19	11	8	8	CD
cord-263267-oj7rmy8m	19	12	which	which	WDT
cord-263267-oj7rmy8m	19	13	indicated	indicate	VBD
cord-263267-oj7rmy8m	19	14	that	that	IN
cord-263267-oj7rmy8m	19	15	hydroxychloroquine	hydroxychloroquine	NN
cord-263267-oj7rmy8m	19	16	might	may	MD
cord-263267-oj7rmy8m	19	17	be	be	VB
cord-263267-oj7rmy8m	19	18	effective	effective	JJ
cord-263267-oj7rmy8m	19	19	,	,	,
cord-263267-oj7rmy8m	19	20	had	have	VBD
cord-263267-oj7rmy8m	19	21	several	several	JJ
cord-263267-oj7rmy8m	19	22	limitations	limitation	NNS
cord-263267-oj7rmy8m	19	23	:	:	:
cord-263267-oj7rmy8m	19	24	a	a	DT
cord-263267-oj7rmy8m	19	25	small	small	JJ
cord-263267-oj7rmy8m	19	26	cohort	cohort	NN
cord-263267-oj7rmy8m	19	27	of	of	IN
cord-263267-oj7rmy8m	19	28	patients	patient	NNS
cord-263267-oj7rmy8m	19	29	,	,	,
cord-263267-oj7rmy8m	19	30	with	with	IN
cord-263267-oj7rmy8m	19	31	only	only	RB
cord-263267-oj7rmy8m	19	32	20	20	CD
cord-263267-oj7rmy8m	19	33	participants	participant	NNS
cord-263267-oj7rmy8m	19	34	who	who	WP
cord-263267-oj7rmy8m	19	35	received	receive	VBD
cord-263267-oj7rmy8m	19	36	hydroxychloroquine	hydroxychloroquine	NNP
cord-263267-oj7rmy8m	19	37	(	(	-LRB-
cord-263267-oj7rmy8m	19	38	six	six	CD
cord-263267-oj7rmy8m	19	39	of	of	IN
cord-263267-oj7rmy8m	19	40	whom	whom	WP
cord-263267-oj7rmy8m	19	41	received	receive	VBD
cord-263267-oj7rmy8m	19	42	azithromycin	azithromycin	NNP
cord-263267-oj7rmy8m	19	43	)	)	-RRB-
cord-263267-oj7rmy8m	19	44	and	and	CC
cord-263267-oj7rmy8m	19	45	16	16	CD
cord-263267-oj7rmy8m	19	46	controls	control	NNS
cord-263267-oj7rmy8m	19	47	included	include	VBN
cord-263267-oj7rmy8m	19	48	in	in	IN
cord-263267-oj7rmy8m	19	49	the	the	DT
cord-263267-oj7rmy8m	19	50	final	final	JJ
cord-263267-oj7rmy8m	19	51	analysis	analysis	NN
cord-263267-oj7rmy8m	19	52	;	;	:
cord-263267-oj7rmy8m	19	53	a	a	DT
cord-263267-oj7rmy8m	19	54	very	very	RB
cord-263267-oj7rmy8m	19	55	short	short	JJ
cord-263267-oj7rmy8m	19	56	observation	observation	NN
cord-263267-oj7rmy8m	19	57	period	period	NN
cord-263267-oj7rmy8m	19	58	(	(	-LRB-
cord-263267-oj7rmy8m	19	59	6	6	CD
cord-263267-oj7rmy8m	19	60	days	day	NNS
cord-263267-oj7rmy8m	19	61	)	)	-RRB-
cord-263267-oj7rmy8m	19	62	;	;	:
cord-263267-oj7rmy8m	19	63	absence	absence	NN
cord-263267-oj7rmy8m	19	64	of	of	IN
cord-263267-oj7rmy8m	19	65	randomisation	randomisation	NN
cord-263267-oj7rmy8m	19	66	,	,	,
cord-263267-oj7rmy8m	19	67	raising	raise	VBG
cord-263267-oj7rmy8m	19	68	concerns	concern	NNS
cord-263267-oj7rmy8m	19	69	about	about	IN
cord-263267-oj7rmy8m	19	70	selection	selection	NN
cord-263267-oj7rmy8m	19	71	bias	bias	NN
cord-263267-oj7rmy8m	19	72	and	and	CC
cord-263267-oj7rmy8m	19	73	imbalance	imbalance	NN
cord-263267-oj7rmy8m	19	74	of	of	IN
cord-263267-oj7rmy8m	19	75	baseline	baseline	JJ
cord-263267-oj7rmy8m	19	76	characteristics	characteristic	NNS
cord-263267-oj7rmy8m	19	77	in	in	IN
cord-263267-oj7rmy8m	19	78	the	the	DT
cord-263267-oj7rmy8m	19	79	intervention	intervention	NN
cord-263267-oj7rmy8m	19	80	and	and	CC
cord-263267-oj7rmy8m	19	81	control	control	NN
cord-263267-oj7rmy8m	19	82	groups	group	NNS
cord-263267-oj7rmy8m	19	83	;	;	:
cord-263267-oj7rmy8m	19	84	and	and	CC
cord-263267-oj7rmy8m	19	85	no	no	DT
cord-263267-oj7rmy8m	19	86	report	report	NN
cord-263267-oj7rmy8m	19	87	of	of	IN
cord-263267-oj7rmy8m	19	88	effects	effect	NNS
cord-263267-oj7rmy8m	19	89	on	on	IN
cord-263267-oj7rmy8m	19	90	clinical	clinical	JJ
cord-263267-oj7rmy8m	19	91	evolution	evolution	NN
cord-263267-oj7rmy8m	19	92	(	(	-LRB-
cord-263267-oj7rmy8m	19	93	6	6	CD
cord-263267-oj7rmy8m	19	94	[	[	-LRB-
cord-263267-oj7rmy8m	19	95	17	17	CD
cord-263267-oj7rmy8m	19	96	%	%	NN
cord-263267-oj7rmy8m	19	97	]	]	-RRB-
cord-263267-oj7rmy8m	19	98	patients	patient	NNS
cord-263267-oj7rmy8m	19	99	were	be	VBD
cord-263267-oj7rmy8m	19	100	asymptomatic	asymptomatic	JJ
cord-263267-oj7rmy8m	19	101	and	and	CC
cord-263267-oj7rmy8m	19	102	only	only	RB
cord-263267-oj7rmy8m	19	103	8	8	CD
cord-263267-oj7rmy8m	19	104	[	[	-LRB-
cord-263267-oj7rmy8m	19	105	22	22	CD
cord-263267-oj7rmy8m	19	106	%	%	NN
cord-263267-oj7rmy8m	19	107	]	]	-RRB-
cord-263267-oj7rmy8m	19	108	had	have	VBD
cord-263267-oj7rmy8m	19	109	pneumonia	pneumonia	NN
cord-263267-oj7rmy8m	19	110	)	)	-RRB-
cord-263267-oj7rmy8m	19	111	.	.	.
cord-263267-oj7rmy8m	20	1	The	the	DT
cord-263267-oj7rmy8m	20	2	second	second	JJ
cord-263267-oj7rmy8m	20	3	French	french	JJ
cord-263267-oj7rmy8m	20	4	study	study	NN
cord-263267-oj7rmy8m	20	5	,	,	,
cord-263267-oj7rmy8m	20	6	although	although	IN
cord-263267-oj7rmy8m	20	7	larger	large	JJR
cord-263267-oj7rmy8m	20	8	,	,	,
cord-263267-oj7rmy8m	20	9	had	have	VBD
cord-263267-oj7rmy8m	20	10	no	no	DT
cord-263267-oj7rmy8m	20	11	control	control	NN
cord-263267-oj7rmy8m	20	12	arm	arm	NN
cord-263267-oj7rmy8m	20	13	.	.	.
cord-263267-oj7rmy8m	21	1	9	9	CD
cord-263267-oj7rmy8m	22	1	Moreover	moreover	RB
cord-263267-oj7rmy8m	22	2	,	,	,
cord-263267-oj7rmy8m	22	3	the	the	DT
cord-263267-oj7rmy8m	22	4	inclusion	inclusion	NN
cord-263267-oj7rmy8m	22	5	and	and	CC
cord-263267-oj7rmy8m	22	6	exclusion	exclusion	NN
cord-263267-oj7rmy8m	22	7	criteria	criterion	NNS
cord-263267-oj7rmy8m	22	8	were	be	VBD
cord-263267-oj7rmy8m	22	9	poorly	poorly	RB
cord-263267-oj7rmy8m	22	10	described	describe	VBN
cord-263267-oj7rmy8m	22	11	,	,	,
cord-263267-oj7rmy8m	22	12	most	most	JJS
cord-263267-oj7rmy8m	22	13	patients	patient	NNS
cord-263267-oj7rmy8m	22	14	(	(	-LRB-
cord-263267-oj7rmy8m	22	15	69	69	CD
cord-263267-oj7rmy8m	22	16	of	of	IN
cord-263267-oj7rmy8m	22	17	75	75	CD
cord-263267-oj7rmy8m	22	18	[	[	-LRB-
cord-263267-oj7rmy8m	22	19	92	92	CD
cord-263267-oj7rmy8m	22	20	%	%	NN
cord-263267-oj7rmy8m	22	21	]	]	-RRB-
cord-263267-oj7rmy8m	22	22	)	)	-RRB-
cord-263267-oj7rmy8m	22	23	had	have	VBD
cord-263267-oj7rmy8m	22	24	a	a	DT
cord-263267-oj7rmy8m	22	25	low	low	JJ
cord-263267-oj7rmy8m	22	26	National	National	NNP
cord-263267-oj7rmy8m	22	27	Early	Early	NNP
cord-263267-oj7rmy8m	22	28	Warning	Warning	NNP
cord-263267-oj7rmy8m	22	29	Score	Score	NNP
cord-263267-oj7rmy8m	22	30	,	,	,
cord-263267-oj7rmy8m	22	31	and	and	CC
cord-263267-oj7rmy8m	22	32	the	the	DT
cord-263267-oj7rmy8m	22	33	overall	overall	JJ
cord-263267-oj7rmy8m	22	34	clinical	clinical	JJ
cord-263267-oj7rmy8m	22	35	outcome	outcome	NN
cord-263267-oj7rmy8m	22	36	was	be	VBD
cord-263267-oj7rmy8m	22	37	similar	similar	JJ
cord-263267-oj7rmy8m	22	38	to	to	IN
cord-263267-oj7rmy8m	23	1	that	that	DT
cord-263267-oj7rmy8m	23	2	reported	report	VBD
cord-263267-oj7rmy8m	23	3	for	for	IN
cord-263267-oj7rmy8m	23	4	untreated	untreated	JJ
cord-263267-oj7rmy8m	23	5	patients	patient	NNS
cord-263267-oj7rmy8m	23	6	with	with	IN
cord-263267-oj7rmy8m	23	7	COVID-19	COVID-19	NNP
cord-263267-oj7rmy8m	23	8	.	.	.
cord-263267-oj7rmy8m	23	9	11	11	CD
cord-263267-oj7rmy8m	24	1	The	the	DT
cord-263267-oj7rmy8m	24	2	combination	combination	NN
cord-263267-oj7rmy8m	24	3	of	of	IN
cord-263267-oj7rmy8m	24	4	hydroxychloroquine	hydroxychloroquine	NN
cord-263267-oj7rmy8m	24	5	and	and	CC
cord-263267-oj7rmy8m	24	6	azithromycin	azithromycin	NNP
cord-263267-oj7rmy8m	24	7	was	be	VBD
cord-263267-oj7rmy8m	24	8	associated	associate	VBN
cord-263267-oj7rmy8m	24	9	with	with	IN
cord-263267-oj7rmy8m	24	10	reduced	reduce	VBN
cord-263267-oj7rmy8m	24	11	viral	viral	JJ
cord-263267-oj7rmy8m	24	12	load	load	NN
cord-263267-oj7rmy8m	24	13	(	(	-LRB-
cord-263267-oj7rmy8m	24	14	83	83	CD
cord-263267-oj7rmy8m	24	15	%	%	NN
cord-263267-oj7rmy8m	24	16	and	and	CC
cord-263267-oj7rmy8m	24	17	93	93	CD
cord-263267-oj7rmy8m	24	18	%	%	NN
cord-263267-oj7rmy8m	24	19	tested	test	VBD
cord-263267-oj7rmy8m	24	20	negative	negative	JJ
cord-263267-oj7rmy8m	24	21	on	on	IN
cord-263267-oj7rmy8m	24	22	days	day	NNS
cord-263267-oj7rmy8m	24	23	7	7	CD
cord-263267-oj7rmy8m	24	24	and	and	CC
cord-263267-oj7rmy8m	24	25	8	8	CD
cord-263267-oj7rmy8m	24	26	,	,	,
cord-263267-oj7rmy8m	24	27	respectively	respectively	RB
cord-263267-oj7rmy8m	24	28	)	)	-RRB-
cord-263267-oj7rmy8m	24	29	,	,	,
cord-263267-oj7rmy8m	24	30	but	but	CC
cord-263267-oj7rmy8m	24	31	no	no	DT
cord-263267-oj7rmy8m	24	32	other	other	JJ
cord-263267-oj7rmy8m	24	33	clinically	clinically	RB
cord-263267-oj7rmy8m	24	34	relevant	relevant	JJ
cord-263267-oj7rmy8m	24	35	outcomes	outcome	NNS
cord-263267-oj7rmy8m	24	36	were	be	VBD
cord-263267-oj7rmy8m	24	37	reported	report	VBN
cord-263267-oj7rmy8m	24	38	.	.	.
cord-263267-oj7rmy8m	25	1	In	in	IN
cord-263267-oj7rmy8m	25	2	a	a	DT
cord-263267-oj7rmy8m	25	3	trial	trial	NN
cord-263267-oj7rmy8m	25	4	in	in	IN
cord-263267-oj7rmy8m	25	5	30	30	CD
cord-263267-oj7rmy8m	25	6	patients	patient	NNS
cord-263267-oj7rmy8m	25	7	with	with	IN
cord-263267-oj7rmy8m	25	8	COVID-19	COVID-19	NNP
cord-263267-oj7rmy8m	25	9	,	,	,
cord-263267-oj7rmy8m	25	10	Jun	Jun	NNP
cord-263267-oj7rmy8m	25	11	Chen	Chen	NNP
cord-263267-oj7rmy8m	25	12	and	and	CC
cord-263267-oj7rmy8m	25	13	colleagues	colleague	NNS
cord-263267-oj7rmy8m	25	14	found	find	VBD
cord-263267-oj7rmy8m	25	15	no	no	DT
cord-263267-oj7rmy8m	25	16	significant	significant	JJ
cord-263267-oj7rmy8m	25	17	difference	difference	NN
cord-263267-oj7rmy8m	25	18	in	in	IN
cord-263267-oj7rmy8m	25	19	nasopharyngeal	nasopharyngeal	JJ
cord-263267-oj7rmy8m	25	20	viral	viral	JJ
cord-263267-oj7rmy8m	25	21	carriage	carriage	NN
cord-263267-oj7rmy8m	25	22	on	on	IN
cord-263267-oj7rmy8m	25	23	day	day	NN
cord-263267-oj7rmy8m	25	24	7	7	CD
cord-263267-oj7rmy8m	25	25	when	when	WRB
cord-263267-oj7rmy8m	25	26	hydroxychloroquine	hydroxychloroquine	NNP
cord-263267-oj7rmy8m	25	27	was	be	VBD
cord-263267-oj7rmy8m	25	28	compared	compare	VBN
cord-263267-oj7rmy8m	25	29	with	with	IN
cord-263267-oj7rmy8m	25	30	local	local	JJ
cord-263267-oj7rmy8m	25	31	standard	standard	NN
cord-263267-oj7rmy8m	25	32	of	of	IN
cord-263267-oj7rmy8m	25	33	care	care	NN
cord-263267-oj7rmy8m	25	34	;	;	:
cord-263267-oj7rmy8m	25	35	however	however	RB
cord-263267-oj7rmy8m	25	36	,	,	,
cord-263267-oj7rmy8m	25	37	concomitant	concomitant	JJ
cord-263267-oj7rmy8m	25	38	antivirals	antiviral	NNS
cord-263267-oj7rmy8m	25	39	were	be	VBD
cord-263267-oj7rmy8m	25	40	given	give	VBN
cord-263267-oj7rmy8m	25	41	,	,	,
cord-263267-oj7rmy8m	25	42	which	which	WDT
cord-263267-oj7rmy8m	25	43	might	may	MD
cord-263267-oj7rmy8m	25	44	have	have	VB
cord-263267-oj7rmy8m	25	45	served	serve	VBN
cord-263267-oj7rmy8m	25	46	as	as	IN
cord-263267-oj7rmy8m	25	47	confounders	confounder	NNS
cord-263267-oj7rmy8m	25	48	when	when	WRB
cord-263267-oj7rmy8m	25	49	interpreting	interpret	VBG
cord-263267-oj7rmy8m	25	50	the	the	DT
cord-263267-oj7rmy8m	25	51	results	result	NNS
cord-263267-oj7rmy8m	25	52	of	of	IN
cord-263267-oj7rmy8m	25	53	this	this	DT
cord-263267-oj7rmy8m	25	54	study	study	NN
cord-263267-oj7rmy8m	25	55	.	.	.
cord-263267-oj7rmy8m	26	1	12	12	CD
cord-263267-oj7rmy8m	27	1	In	in	IN
cord-263267-oj7rmy8m	27	2	a	a	DT
cord-263267-oj7rmy8m	27	3	second	second	JJ
cord-263267-oj7rmy8m	27	4	Chinese	chinese	JJ
cord-263267-oj7rmy8m	27	5	trial	trial	NN
cord-263267-oj7rmy8m	27	6	in	in	IN
cord-263267-oj7rmy8m	27	7	62	62	CD
cord-263267-oj7rmy8m	27	8	patients	patient	NNS
cord-263267-oj7rmy8m	27	9	,	,	,
cord-263267-oj7rmy8m	27	10	Zhaowei	Zhaowei	NNP
cord-263267-oj7rmy8m	27	11	Chen	Chen	NNP
cord-263267-oj7rmy8m	27	12	and	and	CC
cord-263267-oj7rmy8m	27	13	colleagues	colleague	NNS
cord-263267-oj7rmy8m	27	14	showed	show	VBD
cord-263267-oj7rmy8m	27	15	that	that	IN
cord-263267-oj7rmy8m	27	16	hydroxychloroquine	hydroxychloroquine	NN
cord-263267-oj7rmy8m	27	17	treatment	treatment	NN
cord-263267-oj7rmy8m	27	18	was	be	VBD
cord-263267-oj7rmy8m	27	19	associated	associate	VBN
cord-263267-oj7rmy8m	27	20	with	with	IN
cord-263267-oj7rmy8m	27	21	a	a	DT
cord-263267-oj7rmy8m	27	22	shorter	short	JJR
cord-263267-oj7rmy8m	27	23	time	time	NN
cord-263267-oj7rmy8m	27	24	to	to	IN
cord-263267-oj7rmy8m	27	25	clinical	clinical	JJ
cord-263267-oj7rmy8m	27	26	recovery	recovery	NN
cord-263267-oj7rmy8m	27	27	(	(	-LRB-
cord-263267-oj7rmy8m	27	28	temperature	temperature	NN
cord-263267-oj7rmy8m	27	29	and	and	CC
cord-263267-oj7rmy8m	27	30	cough	cough	NN
cord-263267-oj7rmy8m	27	31	)	)	-RRB-
cord-263267-oj7rmy8m	27	32	than	than	IN
cord-263267-oj7rmy8m	27	33	placebo	placebo	NN
cord-263267-oj7rmy8m	27	34	;	;	:
cord-263267-oj7rmy8m	27	35	13	13	CD
cord-263267-oj7rmy8m	27	36	the	the	DT
cord-263267-oj7rmy8m	27	37	participants	participant	NNS
cord-263267-oj7rmy8m	27	38	had	have	VBD
cord-263267-oj7rmy8m	27	39	mild	mild	JJ
cord-263267-oj7rmy8m	27	40	disease	disease	NN
cord-263267-oj7rmy8m	27	41	(	(	-LRB-
cord-263267-oj7rmy8m	27	42	SaO	SaO	NNP
cord-263267-oj7rmy8m	28	1	2	2	LS
cord-263267-oj7rmy8m	28	2	/SpO	/SpO	.
cord-263267-oj7rmy8m	29	1	2	2	LS
cord-263267-oj7rmy8m	29	2	>	>	SYM
cord-263267-oj7rmy8m	29	3	93	93	CD
cord-263267-oj7rmy8m	29	4	%	%	NN
cord-263267-oj7rmy8m	29	5	or	or	CC
cord-263267-oj7rmy8m	29	6	PaO	pao	NN
cord-263267-oj7rmy8m	29	7	2	2	CD
cord-263267-oj7rmy8m	30	1	/FiO	/FiO	NFP
cord-263267-oj7rmy8m	30	2	2	2	CD
cord-263267-oj7rmy8m	30	3	>	>	XX
cord-263267-oj7rmy8m	30	4	300	300	CD
cord-263267-oj7rmy8m	30	5	)	)	-RRB-
cord-263267-oj7rmy8m	31	1	and	and	CC
cord-263267-oj7rmy8m	31	2	it	-PRON-	PRP
cord-263267-oj7rmy8m	31	3	is	be	VBZ
cord-263267-oj7rmy8m	31	4	not	not	RB
cord-263267-oj7rmy8m	31	5	possible	possible	JJ
cord-263267-oj7rmy8m	31	6	to	to	TO
cord-263267-oj7rmy8m	31	7	extrapolate	extrapolate	VB
cord-263267-oj7rmy8m	31	8	these	these	DT
cord-263267-oj7rmy8m	31	9	results	result	NNS
cord-263267-oj7rmy8m	31	10	to	to	TO
cord-263267-oj7rmy8m	31	11	critically	critically	RB
cord-263267-oj7rmy8m	31	12	ill	ill	VB
cord-263267-oj7rmy8m	31	13	patients	patient	NNS
cord-263267-oj7rmy8m	31	14	.	.	.
cord-263267-oj7rmy8m	32	1	A	a	DT
cord-263267-oj7rmy8m	32	2	study	study	NN
cord-263267-oj7rmy8m	32	3	of	of	IN
cord-263267-oj7rmy8m	32	4	11	11	CD
cord-263267-oj7rmy8m	32	5	patients	patient	NNS
cord-263267-oj7rmy8m	32	6	with	with	IN
cord-263267-oj7rmy8m	32	7	COVID-19	covid-19	JJ
cord-263267-oj7rmy8m	32	8	reported	reported	JJ
cord-263267-oj7rmy8m	32	9	persistence	persistence	NN
cord-263267-oj7rmy8m	32	10	of	of	IN
cord-263267-oj7rmy8m	32	11	SARS	SARS	NNP
cord-263267-oj7rmy8m	32	12	-	-	HYPH
cord-263267-oj7rmy8m	32	13	CoV-2	CoV-2	NNP
cord-263267-oj7rmy8m	32	14	in	in	IN
cord-263267-oj7rmy8m	32	15	the	the	DT
cord-263267-oj7rmy8m	32	16	nasopharyngeal	nasopharyngeal	JJ
cord-263267-oj7rmy8m	32	17	swab	swab	NN
cord-263267-oj7rmy8m	32	18	in	in	IN
cord-263267-oj7rmy8m	32	19	8	8	CD
cord-263267-oj7rmy8m	32	20	of	of	IN
cord-263267-oj7rmy8m	32	21	10	10	CD
cord-263267-oj7rmy8m	32	22	patients	patient	NNS
cord-263267-oj7rmy8m	32	23	receiving	receive	VBG
cord-263267-oj7rmy8m	32	24	hydroxychloroquine	hydroxychloroquine	NN
cord-263267-oj7rmy8m	32	25	.	.	.
cord-263267-oj7rmy8m	33	1	14	14	CD
cord-263267-oj7rmy8m	33	2	Third	Third	NNP
cord-263267-oj7rmy8m	33	3	,	,	,
cord-263267-oj7rmy8m	33	4	whether	whether	IN
cord-263267-oj7rmy8m	33	5	viral	viral	JJ
cord-263267-oj7rmy8m	33	6	load	load	NN
cord-263267-oj7rmy8m	33	7	is	be	VBZ
cord-263267-oj7rmy8m	33	8	important	important	JJ
cord-263267-oj7rmy8m	33	9	in	in	IN
cord-263267-oj7rmy8m	33	10	critically	critically	RB
cord-263267-oj7rmy8m	33	11	ill	ill	JJ
cord-263267-oj7rmy8m	33	12	COVID-19	covid-19	CD
cord-263267-oj7rmy8m	33	13	patients	patient	NNS
cord-263267-oj7rmy8m	33	14	or	or	CC
cord-263267-oj7rmy8m	33	15	whether	whether	IN
cord-263267-oj7rmy8m	33	16	progressive	progressive	JJ
cord-263267-oj7rmy8m	33	17	lung	lung	NN
cord-263267-oj7rmy8m	33	18	involvement	involvement	NN
cord-263267-oj7rmy8m	33	19	is	be	VBZ
cord-263267-oj7rmy8m	33	20	related	relate	VBN
cord-263267-oj7rmy8m	33	21	to	to	IN
cord-263267-oj7rmy8m	33	22	an	an	DT
cord-263267-oj7rmy8m	33	23	overwhelming	overwhelming	JJ
cord-263267-oj7rmy8m	33	24	inflammatory	inflammatory	JJ
cord-263267-oj7rmy8m	33	25	response	response	NN
cord-263267-oj7rmy8m	33	26	,	,	,
cord-263267-oj7rmy8m	33	27	unrelated	unrelated	JJ
cord-263267-oj7rmy8m	33	28	to	to	IN
cord-263267-oj7rmy8m	33	29	the	the	DT
cord-263267-oj7rmy8m	33	30	virus	virus	NN
cord-263267-oj7rmy8m	33	31	,	,	,
cord-263267-oj7rmy8m	33	32	remains	remain	VBZ
cord-263267-oj7rmy8m	33	33	to	to	TO
cord-263267-oj7rmy8m	33	34	be	be	VB
cord-263267-oj7rmy8m	33	35	clarified	clarify	VBN
cord-263267-oj7rmy8m	33	36	.	.	.
cord-263267-oj7rmy8m	34	1	An	an	DT
cord-263267-oj7rmy8m	34	2	observational	observational	JJ
cord-263267-oj7rmy8m	34	3	study	study	NN
cord-263267-oj7rmy8m	34	4	found	find	VBD
cord-263267-oj7rmy8m	34	5	that	that	IN
cord-263267-oj7rmy8m	34	6	high	high	JJ
cord-263267-oj7rmy8m	34	7	viral	viral	JJ
cord-263267-oj7rmy8m	34	8	load	load	NN
cord-263267-oj7rmy8m	34	9	was	be	VBD
cord-263267-oj7rmy8m	34	10	associated	associate	VBN
cord-263267-oj7rmy8m	34	11	with	with	IN
cord-263267-oj7rmy8m	34	12	disease	disease	NN
cord-263267-oj7rmy8m	34	13	severity	severity	NN
cord-263267-oj7rmy8m	34	14	;	;	:
cord-263267-oj7rmy8m	34	15	13	13	CD
cord-263267-oj7rmy8m	34	16	however	however	RB
cord-263267-oj7rmy8m	34	17	,	,	,
cord-263267-oj7rmy8m	34	18	the	the	DT
cord-263267-oj7rmy8m	34	19	influence	influence	NN
cord-263267-oj7rmy8m	34	20	of	of	IN
cord-263267-oj7rmy8m	34	21	antiviral	antiviral	JJ
cord-263267-oj7rmy8m	34	22	strategies	strategy	NNS
cord-263267-oj7rmy8m	34	23	in	in	IN
cord-263267-oj7rmy8m	34	24	such	such	JJ
cord-263267-oj7rmy8m	34	25	advanced	advanced	JJ
cord-263267-oj7rmy8m	34	26	forms	form	NNS
cord-263267-oj7rmy8m	34	27	of	of	IN
cord-263267-oj7rmy8m	34	28	the	the	DT
cord-263267-oj7rmy8m	34	29	disease	disease	NN
cord-263267-oj7rmy8m	34	30	remains	remain	VBZ
cord-263267-oj7rmy8m	34	31	unproven	unproven	JJ
cord-263267-oj7rmy8m	34	32	.	.	.
cord-263267-oj7rmy8m	35	1	Fourth	fourth	RB
cord-263267-oj7rmy8m	35	2	,	,	,
cord-263267-oj7rmy8m	35	3	the	the	DT
cord-263267-oj7rmy8m	35	4	search	search	NN
cord-263267-oj7rmy8m	35	5	for	for	IN
cord-263267-oj7rmy8m	35	6	effective	effective	JJ
cord-263267-oj7rmy8m	35	7	new	new	JJ
cord-263267-oj7rmy8m	35	8	drugs	drug	NNS
cord-263267-oj7rmy8m	35	9	requires	require	VBZ
cord-263267-oj7rmy8m	35	10	appropriate	appropriate	JJ
cord-263267-oj7rmy8m	35	11	and	and	CC
cord-263267-oj7rmy8m	35	12	valid	valid	JJ
cord-263267-oj7rmy8m	35	13	trials	trial	NNS
cord-263267-oj7rmy8m	35	14	-	-	HYPH
cord-263267-oj7rmy8m	35	15	ie	ie	JJ
cord-263267-oj7rmy8m	35	16	,	,	,
cord-263267-oj7rmy8m	35	17	prospective	prospective	JJ
cord-263267-oj7rmy8m	35	18	,	,	,
cord-263267-oj7rmy8m	35	19	randomised	randomised	JJ
cord-263267-oj7rmy8m	35	20	,	,	,
cord-263267-oj7rmy8m	35	21	placebo	placebo	NN
cord-263267-oj7rmy8m	35	22	-	-	HYPH
cord-263267-oj7rmy8m	35	23	controlled	control	VBN
cord-263267-oj7rmy8m	35	24	clinical	clinical	JJ
cord-263267-oj7rmy8m	35	25	studies	study	NNS
cord-263267-oj7rmy8m	35	26	.	.	.
cord-263267-oj7rmy8m	36	1	Although	although	IN
cord-263267-oj7rmy8m	36	2	many	many	JJ
cord-263267-oj7rmy8m	36	3	drugs	drug	NNS
cord-263267-oj7rmy8m	36	4	have	have	VBP
cord-263267-oj7rmy8m	36	5	in	in	IN
cord-263267-oj7rmy8m	36	6	-	-	HYPH
cord-263267-oj7rmy8m	36	7	vitro	vitro	FW
cord-263267-oj7rmy8m	36	8	activity	activity	NN
cord-263267-oj7rmy8m	36	9	against	against	IN
cord-263267-oj7rmy8m	36	10	the	the	DT
cord-263267-oj7rmy8m	36	11	virus	virus	NN
cord-263267-oj7rmy8m	36	12	,	,	,
cord-263267-oj7rmy8m	36	13	the	the	DT
cord-263267-oj7rmy8m	36	14	proposal	proposal	NN
cord-263267-oj7rmy8m	36	15	that	that	IN
cord-263267-oj7rmy8m	36	16	such	such	JJ
cord-263267-oj7rmy8m	36	17	drugs	drug	NNS
cord-263267-oj7rmy8m	36	18	might	may	MD
cord-263267-oj7rmy8m	36	19	provide	provide	VB
cord-263267-oj7rmy8m	36	20	more	more	JJR
cord-263267-oj7rmy8m	36	21	benefit	benefit	NN
cord-263267-oj7rmy8m	36	22	than	than	IN
cord-263267-oj7rmy8m	36	23	harm	harm	NN
cord-263267-oj7rmy8m	36	24	is	be	VBZ
cord-263267-oj7rmy8m	36	25	inappropriate	inappropriate	JJ
cord-263267-oj7rmy8m	36	26	in	in	IN
cord-263267-oj7rmy8m	36	27	the	the	DT
cord-263267-oj7rmy8m	36	28	face	face	NN
cord-263267-oj7rmy8m	36	29	of	of	IN
cord-263267-oj7rmy8m	36	30	no	no	DT
cord-263267-oj7rmy8m	36	31	clinical	clinical	JJ
cord-263267-oj7rmy8m	36	32	evidence	evidence	NN
cord-263267-oj7rmy8m	36	33	supporting	support	VBG
cord-263267-oj7rmy8m	36	34	efficacy	efficacy	NN
cord-263267-oj7rmy8m	36	35	and	and	CC
cord-263267-oj7rmy8m	36	36	safety	safety	NN
cord-263267-oj7rmy8m	36	37	in	in	IN
cord-263267-oj7rmy8m	36	38	patients	patient	NNS
cord-263267-oj7rmy8m	36	39	with	with	IN
cord-263267-oj7rmy8m	36	40	COVID-19	COVID-19	NNP
cord-263267-oj7rmy8m	36	41	.	.	.
cord-263267-oj7rmy8m	37	1	International	International	NNP
cord-263267-oj7rmy8m	37	2	multicentre	multicentre	NNP
cord-263267-oj7rmy8m	37	3	studies	study	NNS
cord-263267-oj7rmy8m	37	4	,	,	,
cord-263267-oj7rmy8m	37	5	such	such	JJ
cord-263267-oj7rmy8m	37	6	as	as	IN
cord-263267-oj7rmy8m	37	7	the	the	DT
cord-263267-oj7rmy8m	37	8	Discovery	Discovery	NNP
cord-263267-oj7rmy8m	37	9	study	study	NN
cord-263267-oj7rmy8m	37	10	(	(	-LRB-
cord-263267-oj7rmy8m	37	11	NCT04315948	NCT04315948	NNP
cord-263267-oj7rmy8m	37	12	)	)	-RRB-
cord-263267-oj7rmy8m	37	13	and	and	CC
cord-263267-oj7rmy8m	37	14	the	the	DT
cord-263267-oj7rmy8m	37	15	Solidarity	Solidarity	NNP
cord-263267-oj7rmy8m	37	16	study	study	NN
cord-263267-oj7rmy8m	37	17	(	(	-LRB-
cord-263267-oj7rmy8m	37	18	EudraCT	EudraCT	NNP
cord-263267-oj7rmy8m	37	19	Number	Number	NNP
cord-263267-oj7rmy8m	37	20	2020	2020	CD
cord-263267-oj7rmy8m	37	21	-	-	HYPH
cord-263267-oj7rmy8m	37	22	000982	000982	CD
cord-263267-oj7rmy8m	37	23	-	-	SYM
cord-263267-oj7rmy8m	37	24	18	18	CD
cord-263267-oj7rmy8m	37	25	)	)	-RRB-
cord-263267-oj7rmy8m	37	26	,	,	,
cord-263267-oj7rmy8m	37	27	will	will	MD
cord-263267-oj7rmy8m	37	28	randomise	randomise	VB
cord-263267-oj7rmy8m	37	29	patients	patient	NNS
cord-263267-oj7rmy8m	37	30	with	with	IN
cord-263267-oj7rmy8m	37	31	COVID-19	COVID-19	NNP
cord-263267-oj7rmy8m	37	32	to	to	TO
cord-263267-oj7rmy8m	37	33	receive	receive	VB
cord-263267-oj7rmy8m	37	34	different	different	JJ
cord-263267-oj7rmy8m	37	35	antiviral	antiviral	JJ
cord-263267-oj7rmy8m	37	36	drugs	drug	NNS
cord-263267-oj7rmy8m	37	37	,	,	,
cord-263267-oj7rmy8m	37	38	including	include	VBG
cord-263267-oj7rmy8m	37	39	hydroxychloroquine	hydroxychloroquine	NN
cord-263267-oj7rmy8m	37	40	,	,	,
cord-263267-oj7rmy8m	37	41	in	in	IN
cord-263267-oj7rmy8m	37	42	an	an	DT
cord-263267-oj7rmy8m	37	43	adaptive	adaptive	JJ
cord-263267-oj7rmy8m	37	44	study	study	NN
cord-263267-oj7rmy8m	37	45	design	design	NN
cord-263267-oj7rmy8m	37	46	.	.	.
cord-263267-oj7rmy8m	38	1	These	these	DT
cord-263267-oj7rmy8m	38	2	initiatives	initiative	NNS
cord-263267-oj7rmy8m	38	3	will	will	MD
cord-263267-oj7rmy8m	38	4	provide	provide	VB
cord-263267-oj7rmy8m	38	5	important	important	JJ
cord-263267-oj7rmy8m	38	6	data	datum	NNS
cord-263267-oj7rmy8m	38	7	to	to	TO
cord-263267-oj7rmy8m	38	8	guide	guide	VB
cord-263267-oj7rmy8m	38	9	the	the	DT
cord-263267-oj7rmy8m	38	10	management	management	NN
cord-263267-oj7rmy8m	38	11	of	of	IN
cord-263267-oj7rmy8m	38	12	patients	patient	NNS
cord-263267-oj7rmy8m	38	13	with	with	IN
cord-263267-oj7rmy8m	38	14	COVID-19	covid-19	VB
cord-263267-oj7rmy8m	38	15	and	and	CC
cord-263267-oj7rmy8m	38	16	help	help	VB
cord-263267-oj7rmy8m	38	17	to	to	TO
cord-263267-oj7rmy8m	38	18	improve	improve	VB
cord-263267-oj7rmy8m	38	19	understanding	understanding	NN
cord-263267-oj7rmy8m	38	20	of	of	IN
cord-263267-oj7rmy8m	38	21	the	the	DT
cord-263267-oj7rmy8m	38	22	effects	effect	NNS
cord-263267-oj7rmy8m	38	23	of	of	IN
cord-263267-oj7rmy8m	38	24	antiviral	antiviral	JJ
cord-263267-oj7rmy8m	38	25	therapies	therapy	NNS
cord-263267-oj7rmy8m	38	26	in	in	IN
cord-263267-oj7rmy8m	38	27	critically	critically	RB
cord-263267-oj7rmy8m	38	28	ill	ill	JJ
cord-263267-oj7rmy8m	38	29	patients	patient	NNS
cord-263267-oj7rmy8m	38	30	.	.	.
cord-263267-oj7rmy8m	39	1	Whether	whether	IN
cord-263267-oj7rmy8m	39	2	antimalarial	antimalarial	JJ
cord-263267-oj7rmy8m	39	3	drugs	drug	NNS
cord-263267-oj7rmy8m	39	4	could	could	MD
cord-263267-oj7rmy8m	39	5	be	be	VB
cord-263267-oj7rmy8m	39	6	effective	effective	JJ
cord-263267-oj7rmy8m	39	7	in	in	IN
cord-263267-oj7rmy8m	39	8	changing	change	VBG
cord-263267-oj7rmy8m	39	9	the	the	DT
cord-263267-oj7rmy8m	39	10	disease	disease	NN
cord-263267-oj7rmy8m	39	11	course	course	NN
cord-263267-oj7rmy8m	39	12	in	in	IN
cord-263267-oj7rmy8m	39	13	patients	patient	NNS
cord-263267-oj7rmy8m	39	14	with	with	IN
cord-263267-oj7rmy8m	39	15	severe	severe	JJ
cord-263267-oj7rmy8m	39	16	COVID-19-in	COVID-19-in	NNP
cord-263267-oj7rmy8m	39	17	particular	particular	JJ
cord-263267-oj7rmy8m	39	18	,	,	,
cord-263267-oj7rmy8m	39	19	in	in	IN
cord-263267-oj7rmy8m	39	20	cases	case	NNS
cord-263267-oj7rmy8m	39	21	requiring	require	VBG
cord-263267-oj7rmy8m	39	22	ICU	ICU	NNP
cord-263267-oj7rmy8m	39	23	admission	admission	NN
cord-263267-oj7rmy8m	39	24	-	-	HYPH
cord-263267-oj7rmy8m	39	25	remains	remain	VBZ
cord-263267-oj7rmy8m	39	26	unknown	unknown	JJ
cord-263267-oj7rmy8m	39	27	.	.	.
cord-263267-oj7rmy8m	40	1	Moreover	moreover	RB
cord-263267-oj7rmy8m	40	2	,	,	,
cord-263267-oj7rmy8m	40	3	for	for	IN
cord-263267-oj7rmy8m	40	4	patients	patient	NNS
cord-263267-oj7rmy8m	40	5	receiving	receive	VBG
cord-263267-oj7rmy8m	40	6	antimalarial	antimalarial	JJ
cord-263267-oj7rmy8m	40	7	drugs	drug	NNS
cord-263267-oj7rmy8m	40	8	who	who	WP
cord-263267-oj7rmy8m	40	9	then	then	RB
cord-263267-oj7rmy8m	40	10	require	require	VBP
cord-263267-oj7rmy8m	40	11	ICU	ICU	NNP
cord-263267-oj7rmy8m	40	12	admission	admission	NN
cord-263267-oj7rmy8m	40	13	,	,	,
cord-263267-oj7rmy8m	40	14	it	-PRON-	PRP
cord-263267-oj7rmy8m	40	15	is	be	VBZ
cord-263267-oj7rmy8m	40	16	not	not	RB
cord-263267-oj7rmy8m	40	17	known	know	VBN
cord-263267-oj7rmy8m	40	18	whether	whether	IN
cord-263267-oj7rmy8m	40	19	the	the	DT
cord-263267-oj7rmy8m	40	20	drug	drug	NN
cord-263267-oj7rmy8m	40	21	should	should	MD
cord-263267-oj7rmy8m	40	22	be	be	VB
cord-263267-oj7rmy8m	40	23	continued	continue	VBN
cord-263267-oj7rmy8m	40	24	or	or	CC
cord-263267-oj7rmy8m	40	25	considered	consider	VBN
cord-263267-oj7rmy8m	40	26	clinically	clinically	RB
cord-263267-oj7rmy8m	40	27	ineffective	ineffective	JJ
cord-263267-oj7rmy8m	40	28	and	and	CC
cord-263267-oj7rmy8m	40	29	stopped	stop	VBD
cord-263267-oj7rmy8m	40	30	.	.	.
cord-263267-oj7rmy8m	41	1	Assessing	assess	VBG
cord-263267-oj7rmy8m	41	2	viral	viral	JJ
cord-263267-oj7rmy8m	41	3	load	load	NN
cord-263267-oj7rmy8m	41	4	,	,	,
cord-263267-oj7rmy8m	41	5	either	either	CC
cord-263267-oj7rmy8m	41	6	on	on	IN
cord-263267-oj7rmy8m	41	7	a	a	DT
cord-263267-oj7rmy8m	41	8	nasopharyngeal	nasopharyngeal	JJ
cord-263267-oj7rmy8m	41	9	swab	swab	NN
cord-263267-oj7rmy8m	41	10	or	or	CC
cord-263267-oj7rmy8m	41	11	in	in	IN
cord-263267-oj7rmy8m	41	12	bronchoalveolar	bronchoalveolar	NNP
cord-263267-oj7rmy8m	41	13	lavage	lavage	NN
cord-263267-oj7rmy8m	41	14	fluid	fluid	NN
cord-263267-oj7rmy8m	41	15	,	,	,
cord-263267-oj7rmy8m	41	16	might	may	MD
cord-263267-oj7rmy8m	41	17	be	be	VB
cord-263267-oj7rmy8m	41	18	of	of	IN
cord-263267-oj7rmy8m	41	19	use	use	NN
cord-263267-oj7rmy8m	41	20	in	in	IN
cord-263267-oj7rmy8m	41	21	understanding	understanding	NN
cord-263267-oj7rmy8m	41	22	whether	whether	IN
cord-263267-oj7rmy8m	41	23	targeting	target	VBG
cord-263267-oj7rmy8m	41	24	viral	viral	JJ
cord-263267-oj7rmy8m	41	25	replication	replication	NN
cord-263267-oj7rmy8m	41	26	,	,	,
cord-263267-oj7rmy8m	41	27	rather	rather	RB
cord-263267-oj7rmy8m	41	28	than	than	IN
cord-263267-oj7rmy8m	41	29	other	other	JJ
cord-263267-oj7rmy8m	41	30	injurious	injurious	JJ
cord-263267-oj7rmy8m	41	31	lung	lung	NN
cord-263267-oj7rmy8m	41	32	pathways	pathway	NNS
cord-263267-oj7rmy8m	41	33	,	,	,
cord-263267-oj7rmy8m	41	34	is	be	VBZ
cord-263267-oj7rmy8m	41	35	a	a	DT
cord-263267-oj7rmy8m	41	36	reasonable	reasonable	JJ
cord-263267-oj7rmy8m	41	37	therapeutic	therapeutic	JJ
cord-263267-oj7rmy8m	41	38	strategy	strategy	NN
cord-263267-oj7rmy8m	41	39	.	.	.
cord-263267-oj7rmy8m	42	1	Future	future	JJ
cord-263267-oj7rmy8m	42	2	studies	study	NNS
cord-263267-oj7rmy8m	42	3	should	should	MD
cord-263267-oj7rmy8m	42	4	aim	aim	VB
cord-263267-oj7rmy8m	42	5	to	to	TO
cord-263267-oj7rmy8m	42	6	clarify	clarify	VB
cord-263267-oj7rmy8m	42	7	the	the	DT
cord-263267-oj7rmy8m	42	8	precise	precise	JJ
cord-263267-oj7rmy8m	42	9	role	role	NN
cord-263267-oj7rmy8m	42	10	,	,	,
cord-263267-oj7rmy8m	42	11	if	if	IN
cord-263267-oj7rmy8m	42	12	any	any	DT
cord-263267-oj7rmy8m	42	13	,	,	,
cord-263267-oj7rmy8m	42	14	of	of	IN
cord-263267-oj7rmy8m	42	15	chloroquine	chloroquine	NN
cord-263267-oj7rmy8m	42	16	and	and	CC
cord-263267-oj7rmy8m	42	17	hydroxychloroquine	hydroxychloroquine	NN
cord-263267-oj7rmy8m	42	18	in	in	IN
cord-263267-oj7rmy8m	42	19	critically	critically	RB
cord-263267-oj7rmy8m	42	20	ill	ill	JJ
cord-263267-oj7rmy8m	42	21	patients	patient	NNS
cord-263267-oj7rmy8m	42	22	with	with	IN
cord-263267-oj7rmy8m	42	23	COVID-19	COVID-19	NNP
cord-263267-oj7rmy8m	42	24	.	.	.
cord-263267-oj7rmy8m	43	1	We	-PRON-	PRP
cord-263267-oj7rmy8m	43	2	declare	declare	VBP
cord-263267-oj7rmy8m	43	3	no	no	DT
cord-263267-oj7rmy8m	43	4	competing	compete	VBG
cord-263267-oj7rmy8m	43	5	interests	interest	NNS
cord-263267-oj7rmy8m	43	6	.	.	.
cord-263267-oj7rmy8m	43	7	 	 	_SP
cord-263267-oj7rmy8m	44	1	A	a	DT
cord-263267-oj7rmy8m	44	2	systematic	systematic	JJ
cord-263267-oj7rmy8m	44	3	review	review	NN
cord-263267-oj7rmy8m	44	4	on	on	IN
cord-263267-oj7rmy8m	44	5	the	the	DT
cord-263267-oj7rmy8m	44	6	efficacy	efficacy	NN
cord-263267-oj7rmy8m	44	7	and	and	CC
cord-263267-oj7rmy8m	44	8	safety	safety	NN
cord-263267-oj7rmy8m	44	9	of	of	IN
cord-263267-oj7rmy8m	44	10	chloroquine	chloroquine	NN
cord-263267-oj7rmy8m	44	11	for	for	IN
cord-263267-oj7rmy8m	44	12	the	the	DT
cord-263267-oj7rmy8m	44	13	treatment	treatment	NN
cord-263267-oj7rmy8m	44	14	of	of	IN
cord-263267-oj7rmy8m	44	15	COVID-19	COVID-19	NNP
cord-263267-oj7rmy8m	44	16	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-263267-oj7rmy8m	44	17	and	and	CC
cord-263267-oj7rmy8m	44	18	azithromycin	azithromycin	NNP
cord-263267-oj7rmy8m	44	19	as	as	IN
cord-263267-oj7rmy8m	44	20	a	a	DT
cord-263267-oj7rmy8m	44	21	treatment	treatment	NN
cord-263267-oj7rmy8m	44	22	of	of	IN
cord-263267-oj7rmy8m	44	23	COVID-19	covid-19	NN
cord-263267-oj7rmy8m	44	24	:	:	:
cord-263267-oj7rmy8m	44	25	results	result	NNS
cord-263267-oj7rmy8m	44	26	of	of	IN
cord-263267-oj7rmy8m	44	27	an	an	DT
cord-263267-oj7rmy8m	44	28	open	open	JJ
cord-263267-oj7rmy8m	44	29	-	-	HYPH
cord-263267-oj7rmy8m	44	30	label	label	NN
cord-263267-oj7rmy8m	44	31	non	non	JJ
cord-263267-oj7rmy8m	44	32	-	-	JJ
cord-263267-oj7rmy8m	44	33	randomized	randomized	JJ
cord-263267-oj7rmy8m	44	34	clinical	clinical	JJ
cord-263267-oj7rmy8m	44	35	trial	trial	NN
cord-263267-oj7rmy8m	44	36	Clinical	clinical	JJ
cord-263267-oj7rmy8m	44	37	and	and	CC
cord-263267-oj7rmy8m	44	38	microbiological	microbiological	JJ
cord-263267-oj7rmy8m	44	39	effect	effect	NN
cord-263267-oj7rmy8m	44	40	of	of	IN
cord-263267-oj7rmy8m	44	41	a	a	DT
cord-263267-oj7rmy8m	44	42	combination	combination	NN
cord-263267-oj7rmy8m	44	43	of	of	IN
cord-263267-oj7rmy8m	44	44	hydroxychloroquine	hydroxychloroquine	NN
cord-263267-oj7rmy8m	44	45	and	and	CC
cord-263267-oj7rmy8m	44	46	azithromycin	azithromycin	NNP
cord-263267-oj7rmy8m	44	47	in	in	IN
cord-263267-oj7rmy8m	44	48	80	80	CD
cord-263267-oj7rmy8m	44	49	COVID-19	covid-19	JJ
cord-263267-oj7rmy8m	44	50	patients	patient	NNS
cord-263267-oj7rmy8m	44	51	with	with	IN
cord-263267-oj7rmy8m	44	52	at	at	RB
cord-263267-oj7rmy8m	44	53	least	least	JJS
cord-263267-oj7rmy8m	44	54	a	a	DT
cord-263267-oj7rmy8m	44	55	six	six	CD
cord-263267-oj7rmy8m	44	56	-	-	HYPH
cord-263267-oj7rmy8m	44	57	day	day	NN
cord-263267-oj7rmy8m	44	58	follow	follow	VB
cord-263267-oj7rmy8m	44	59	up	up	RP
cord-263267-oj7rmy8m	44	60	:	:	:
cord-263267-oj7rmy8m	44	61	an	an	DT
cord-263267-oj7rmy8m	44	62	observational	observational	JJ
cord-263267-oj7rmy8m	44	63	study	study	NN
cord-263267-oj7rmy8m	44	64	Surviving	Surviving	NNP
cord-263267-oj7rmy8m	44	65	Sepsis	Sepsis	NNP
cord-263267-oj7rmy8m	44	66	Campaign	Campaign	NNP
cord-263267-oj7rmy8m	44	67	:	:	:
cord-263267-oj7rmy8m	44	68	guidelines	guideline	NNS
cord-263267-oj7rmy8m	44	69	on	on	IN
cord-263267-oj7rmy8m	44	70	the	the	DT
cord-263267-oj7rmy8m	44	71	management	management	NN
cord-263267-oj7rmy8m	44	72	of	of	IN
cord-263267-oj7rmy8m	44	73	critically	critically	RB
cord-263267-oj7rmy8m	44	74	ill	ill	JJ
cord-263267-oj7rmy8m	44	75	adults	adult	NNS
cord-263267-oj7rmy8m	44	76	with	with	IN
cord-263267-oj7rmy8m	44	77	Coronavirus	Coronavirus	NNP
cord-263267-oj7rmy8m	44	78	Disease	Disease	NNP
cord-263267-oj7rmy8m	44	79	2019	2019	CD
cord-263267-oj7rmy8m	45	1	(	(	-LRB-
cord-263267-oj7rmy8m	45	2	COVID-19	covid-19	VB
cord-263267-oj7rmy8m	45	3	)	)	-RRB-
cord-263267-oj7rmy8m	45	4	Clinical	clinical	JJ
cord-263267-oj7rmy8m	45	5	characteristics	characteristic	NNS
cord-263267-oj7rmy8m	45	6	of	of	IN
cord-263267-oj7rmy8m	45	7	coronavirus	coronavirus	NN
cord-263267-oj7rmy8m	45	8	disease	disease	NN
cord-263267-oj7rmy8m	45	9	2019	2019	CD
cord-263267-oj7rmy8m	45	10	in	in	IN
cord-263267-oj7rmy8m	45	11	China	China	NNP
cord-263267-oj7rmy8m	46	1	A	a	DT
cord-263267-oj7rmy8m	46	2	pilot	pilot	NN
cord-263267-oj7rmy8m	46	3	study	study	NN
cord-263267-oj7rmy8m	46	4	of	of	IN
cord-263267-oj7rmy8m	46	5	hydroxychloroquine	hydroxychloroquine	NNP
cord-263267-oj7rmy8m	46	6	in	in	IN
cord-263267-oj7rmy8m	46	7	treatment	treatment	NN
cord-263267-oj7rmy8m	46	8	of	of	IN
cord-263267-oj7rmy8m	46	9	patients	patient	NNS
cord-263267-oj7rmy8m	46	10	with	with	IN
cord-263267-oj7rmy8m	46	11	common	common	JJ
cord-263267-oj7rmy8m	46	12	coronavirus	coronavirus	NN
cord-263267-oj7rmy8m	46	13	disease-19	disease-19	,
cord-263267-oj7rmy8m	46	14	(	(	-LRB-
cord-263267-oj7rmy8m	46	15	COVID-19	COVID-19	NNP
cord-263267-oj7rmy8m	46	16	)	)	-RRB-
cord-263267-oj7rmy8m	46	17	Efficacy	Efficacy	NNP
cord-263267-oj7rmy8m	46	18	of	of	IN
cord-263267-oj7rmy8m	46	19	hydroxychloroquine	hydroxychloroquine	NN
cord-263267-oj7rmy8m	46	20	in	in	IN
cord-263267-oj7rmy8m	46	21	patients	patient	NNS
cord-263267-oj7rmy8m	46	22	with	with	IN
cord-263267-oj7rmy8m	46	23	COVID-19	covid-19	NN
cord-263267-oj7rmy8m	46	24	:	:	:
cord-263267-oj7rmy8m	46	25	results	result	NNS
cord-263267-oj7rmy8m	46	26	of	of	IN
cord-263267-oj7rmy8m	46	27	a	a	DT
cord-263267-oj7rmy8m	46	28	randomized	randomized	JJ
cord-263267-oj7rmy8m	46	29	clinical	clinical	JJ
cord-263267-oj7rmy8m	46	30	trial	trial	NN
cord-263267-oj7rmy8m	47	1	No	no	DT
cord-263267-oj7rmy8m	47	2	evidence	evidence	NN
cord-263267-oj7rmy8m	47	3	of	of	IN
cord-263267-oj7rmy8m	47	4	rapid	rapid	JJ
cord-263267-oj7rmy8m	47	5	antiviral	antiviral	JJ
cord-263267-oj7rmy8m	47	6	clearance	clearance	NN
cord-263267-oj7rmy8m	47	7	or	or	CC
cord-263267-oj7rmy8m	47	8	clinical	clinical	JJ
cord-263267-oj7rmy8m	47	9	benefit	benefit	NN
cord-263267-oj7rmy8m	47	10	with	with	IN
cord-263267-oj7rmy8m	47	11	the	the	DT
cord-263267-oj7rmy8m	47	12	combination	combination	NN
cord-263267-oj7rmy8m	47	13	of	of	IN
cord-263267-oj7rmy8m	47	14	hydroxychloroquine	hydroxychloroquine	NN
cord-263267-oj7rmy8m	47	15	and	and	CC
cord-263267-oj7rmy8m	47	16	azithromycin	azithromycin	NNP
cord-263267-oj7rmy8m	47	17	in	in	IN
cord-263267-oj7rmy8m	47	18	patients	patient	NNS
cord-263267-oj7rmy8m	47	19	with	with	IN
cord-263267-oj7rmy8m	47	20	severe	severe	JJ
cord-263267-oj7rmy8m	47	21	COVID-19	covid-19	CD
cord-263267-oj7rmy8m	47	22	infection	infection	NN